Insight

Jul 19, 2024, 13:45

Homologous recombination deficient breast cancer are more sensitive to chemo-radiotherapy

Memorial Sloan Kettering Radiation Oncology shared on X about a recent paper titled “Increased synthetic cytotoxicity of combinatorial chemo-radiotherapy in homologous recombination deficient tumors” in International Journal of Radiation Oncology, Biology, Physics.

Authors. Jennifer Ma, Rachna Shah, Andrew C. Bell, Jorge S. Reis-Filho, Nadeem Riaz, Simon N. Powell et al.

Homologous recombination

“New in International Journal of Radiation Oncology, Biology and Physics – The Red Journal from Dr Jennifer Ma et al: Homologous recombination deficient breast cancer (HRD via BRCA 1/2, functional test or mutational signature) are more sensitive to chemoRT vs isogenic controls or tumors without HRD mutational signature.”

Source: Memorial Sloan Kettering Radiation Oncology/X

Andrew C. Bell BRCA Breast Cancer cancer chemoRT IJROBP IJROBP - The Red Journal International Journal of Radiation Oncology Biology Physics Jennifer Ma Jorge S. Reis-Filho Memorial Sloan Kettering Radiation Oncology Nadeem Riaz OncoDaily Oncology Rachna Shah Simon N. Powell

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity